MoonLake Immunotherapeutics is trying to convert a contested hidradenitis package into a first commercial franchise after last autumn's Phase Three wobble erased most of the prior valuation. The April pre-BLA meeting with the Food and Drug Administration aligned the company and the agency on a hidradenitis filing path that leans on the earlier MIRA study for substantial evidence and folds adolescent VELA-TEEN data into a proposed label covering patients aged twelve and above. That meeting is the event that turned a statistical scare into a still-live regulatory calendar. The equity now prices a single Nanobody against an already approved dual interleukin competitor rather than a clean best-in-disease story.
Cash was rebuilt in June through a follow-on and at-the-market sales, leaving $537 million of liquidity and a stated runway into mid-2028. The same quarter delivered absolute IZAR one response rates in biologic-naive psoriatic arthritis that look commercially relevant, yet the placebo comparison stays blinded until the twin IZAR program finishes. Remaining Hercules capacity is still gated on later regulatory and clinical milestones, so the headline facility size is not spendable capital.
The investment debate is whether the agency accepts a hidradenitis application that mixes a clean VELA one win with a VELA two composite miss, and whether the eventual label can support a launch against bimekizumab. The late September filing window either produces a review clock that the current cash stack can fund through a second-half 2027 launch, or the September 2025 miss reappears as a refuse-to-file or a narrowed label.